Saltar al contenido
Merck

L0376000

Leuprorelin

European Pharmacopoeia (EP) Reference Standard

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Acerca de este artículo

Fórmula empírica (notación de Hill):
C59H84N16O12
Número CAS:
53714-56-0
Peso molecular:
1209.40
UNSPSC Code:
41116107
NACRES:
NA.24

Documentos clave

Ver Toda la documentación
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

SMILES string

[nH]1cncc1C[C@H](NC(=O)C6NC(=O)CC6)C(=O)N[C@@H](Cc4c5c([nH]c4)cccc5)C(=O)NC(CO)C(=O)N[C@@H](Cc3ccc(cc3)O)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2[C@@H](CCC2)C(=O)NCC.OC(=O)C

InChI

1S/C57H80N16O12.C2H4O2/c1-6-61-53(82)44-14-10-22-73(44)56(85)39(13-9-21-62-57(58)59)66-54(83)46(30(2)3)72-55(84)47(31(4)5)71-51(80)40(23-32-15-17-35(75)18-16-32)67-52(81)43(28-74)70-49(78)41(24-33-26-63-37-12-8-7-11-36(33)37)68-50(79)42(25-34-27-60-29-64-34)69-48(77)38-19-20-45(76)65-38;1-2(3)4/h7-8,11-12,15-18,26-27,29-31,38-44,46-47,63,74-75H,6,9-10,13-14,19-25,28H2,1-5H3,(H,60,64)(H,61,82)(H,65,76)(H,66,83)(H,67,81)(H,68,79)(H,69,77)(H,70,78)(H,71,80)(H,72,84)(H4,58,59,62);1H3,(H,3,4)/t38?,39-,40-,41-,42-,43?,44-,46-,47+;/m0./s1

InChI key

ATCUBNJYGKGZGL-GZROYGCLSA-N

grade

pharmaceutical primary standard

API family

leuprorelin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Categorías relacionadas

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the Issuing Pharmacopoeia.

For further information and support please go to the website of the issuing Pharmacopoeia.

It is a synthetic nonapeptide analogue of the hypothalamic peptide, gonadorelin. It is obtained by chemical synthesis and is available as an acetate.

Application

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia. Their suitability for any other use is not guaranteed and is the sole responsibility of the user. This standard is not intended for human or animal use.
Established for the preparation of reference solutions (a) in the assay and testing of related substances of leuprorelin using liquid chromatography (General text 2.2.29), according to the monograph 1442 of European Pharmacopeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Piero Periti et al.
Clinical pharmacokinetics, 41(7), 485-504 (2002-06-27)
Leuprorelin acetate is a synthetic agonist analogue of gonadotropin-releasing hormone. Continued leuprorelin administration results in suppression of gonadal steroid synthesis, resulting in pharmacological castration. Since leuprorelin is a peptide, it is orally inactive and generally given subcutaneously or intramuscularly. Sustained
Leuprorelin
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 3073-3074 (2008)
K Yasukawa et al.
The British journal of dermatology, 152(5), 1045-1047 (2005-05-13)
Leuprorelin acetate, an agonist of gonadotropin-releasing hormone (GnRH), is indicated in the treatment of prostate cancer. Recently, depot formulations of leuprorelin acetate have been widely used. We report three patients who showed a granulomatous reaction after treatment using a leuprorelin
R Berges et al.
Current medical research and opinion, 22(4), 649-655 (2006-05-11)
Leuprorelin is a well known luteinising hormone releasing hormone (LHRH) agonist. The drug is effective in the treatment of advanced prostate cancer and is well tolerated. This article reviews published literature (based on a search of PubMed, EMBASE and Biosis
G L Plosker et al.
Drugs, 48(6), 930-967 (1994-12-01)
Leuprorelin (leuprolide acetate) is a gonadotrophin-releasing hormone (GnRH) analogue used to treat a wide range of sex hormone-related disorders including advanced prostatic cancer, endometriosis and precocious puberty. It acts primarily on the anterior pituitary, inducing a transient early rise in
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico